Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000789599> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2000789599 endingPage "412" @default.
- W2000789599 startingPage "401" @default.
- W2000789599 abstract "In the event of failure of maintenance therapy with biologic agents for moderate to severe plaque psoriasis, the possible approaches are to switch to another agent or escalate the dose (generally by increased dosing frequency). Knowledge of the economic impact of the 2 alternatives would be extremely useful for therapeutic decision making.The present analysis aimed to determine the moment in which the annualized additional cost of escalation exceeds a specified cost overrun.Based on the purchase cost (average wholesale price) of approved biologics for the treatment of moderate to severe psoriasis, the number of weeks of escalation of the initial biologic until the annualized cost of dose escalation ran €1000 over the cost of switching to another biologic was calculated for a typical patient weighing 80 kg.According to this model, switching to another biologic is always cost effective, with adalimumab followed by ustekinumab the best choices in this respect. Ustekinumab allows for a longer trial escalation period (2 to 4 injections) before the cost overrun threshold is reached, whereas the threshold is reached in a single infusion if a patient is on infliximab.The study does not take into account the differential efficacy of the various biologic therapies as rescue treatment for failure of maintenance therapy given the lack of scientific evidence. The results nevertheless show substantial differences in the period during which treatment can be intensified before reaching the preset cost overrun." @default.
- W2000789599 created "2016-06-24" @default.
- W2000789599 creator A5033015474 @default.
- W2000789599 date "2014-05-01" @default.
- W2000789599 modified "2023-10-02" @default.
- W2000789599 title "Tratamiento de la psoriasis en placas moderada a grave con fármacos biológicos: análisis del sobrecoste de la intensificación temporal frente a cambio a otro biológico en caso de fracaso secundario" @default.
- W2000789599 cites W1986491516 @default.
- W2000789599 cites W2010263500 @default.
- W2000789599 cites W2023773454 @default.
- W2000789599 cites W2032856893 @default.
- W2000789599 cites W2060132373 @default.
- W2000789599 cites W2093517509 @default.
- W2000789599 cites W2102417014 @default.
- W2000789599 cites W2109633277 @default.
- W2000789599 cites W2137012986 @default.
- W2000789599 cites W2145492843 @default.
- W2000789599 cites W2149566497 @default.
- W2000789599 cites W2158420662 @default.
- W2000789599 cites W2171309002 @default.
- W2000789599 doi "https://doi.org/10.1016/j.ad.2013.10.014" @default.
- W2000789599 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24444743" @default.
- W2000789599 hasPublicationYear "2014" @default.
- W2000789599 type Work @default.
- W2000789599 sameAs 2000789599 @default.
- W2000789599 citedByCount "21" @default.
- W2000789599 countsByYear W20007895992014 @default.
- W2000789599 countsByYear W20007895992015 @default.
- W2000789599 countsByYear W20007895992016 @default.
- W2000789599 countsByYear W20007895992017 @default.
- W2000789599 countsByYear W20007895992018 @default.
- W2000789599 countsByYear W20007895992019 @default.
- W2000789599 countsByYear W20007895992020 @default.
- W2000789599 crossrefType "journal-article" @default.
- W2000789599 hasAuthorship W2000789599A5033015474 @default.
- W2000789599 hasConcept C126322002 @default.
- W2000789599 hasConcept C16005928 @default.
- W2000789599 hasConcept C2777138892 @default.
- W2000789599 hasConcept C2777288759 @default.
- W2000789599 hasConcept C2778975655 @default.
- W2000789599 hasConcept C2779134260 @default.
- W2000789599 hasConcept C2780132546 @default.
- W2000789599 hasConcept C2780564577 @default.
- W2000789599 hasConcept C71924100 @default.
- W2000789599 hasConceptScore W2000789599C126322002 @default.
- W2000789599 hasConceptScore W2000789599C16005928 @default.
- W2000789599 hasConceptScore W2000789599C2777138892 @default.
- W2000789599 hasConceptScore W2000789599C2777288759 @default.
- W2000789599 hasConceptScore W2000789599C2778975655 @default.
- W2000789599 hasConceptScore W2000789599C2779134260 @default.
- W2000789599 hasConceptScore W2000789599C2780132546 @default.
- W2000789599 hasConceptScore W2000789599C2780564577 @default.
- W2000789599 hasConceptScore W2000789599C71924100 @default.
- W2000789599 hasIssue "4" @default.
- W2000789599 hasLocation W20007895991 @default.
- W2000789599 hasLocation W20007895992 @default.
- W2000789599 hasOpenAccess W2000789599 @default.
- W2000789599 hasPrimaryLocation W20007895991 @default.
- W2000789599 hasRelatedWork W1485937383 @default.
- W2000789599 hasRelatedWork W1920699911 @default.
- W2000789599 hasRelatedWork W2014044177 @default.
- W2000789599 hasRelatedWork W2062156425 @default.
- W2000789599 hasRelatedWork W2109525818 @default.
- W2000789599 hasRelatedWork W2475288067 @default.
- W2000789599 hasRelatedWork W2514431145 @default.
- W2000789599 hasRelatedWork W2610304240 @default.
- W2000789599 hasRelatedWork W2801369461 @default.
- W2000789599 hasRelatedWork W2807259109 @default.
- W2000789599 hasVolume "105" @default.
- W2000789599 isParatext "false" @default.
- W2000789599 isRetracted "false" @default.
- W2000789599 magId "2000789599" @default.
- W2000789599 workType "article" @default.